Evidence map›Paper›PMID 33723801›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2021

Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry.

Phyllis van der Ploeg, Laura A M van Lieshout, Anja van de Stolpe, Steven L Bosch, Marjolein H F M Lentjes-Beer, Ruud L M Bekkers, Jurgen M J Piek

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Phyllis van der PloegDepartment of Obstetrics and Gynecology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands. phyllis.vd.ploeg@catharinaziekenhuis.nl.ORCID http://orcid.org/0000-0002-5099-7473
Laura A M van LieshoutDepartment of Obstetrics and Gynecology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Anja van de StolpeMolecular Pathway Dx, Philips, Eindhoven, The Netherlands.
Steven L BoschLaboratory for Pathology and Medical Microbiology (Stichting PAMM), Eindhoven, The Netherlands.
Marjolein H F M Lentjes-BeerLaboratory for Pathology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
Ruud L M BekkersDepartment of Obstetrics and Gynecology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Jurgen M J PiekDepartment of Obstetrics and Gynecology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands. jurgen.piek@catharinaziekenhuis.nl.
Radboud University Nijmegen · NLJeroen Bosch Ziekenhuis · NLPAMM · NLPhilips (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnti-estrogen therapy may be used as a palliative treatment option in high-grade serous ovarian carcinomas (HGSC). However, clinical implementation is limited as the use of estrogen receptor (ER) protein expression by immunohistochemistry remains insufficient in predicting therapy response. To determine the accuracy of ER protein expression as a marker for ER signaling pathway activity, we aimed to correlate ER protein expression to functional ER signaling pathway activity in HGSC.

methodsImmunohistochemical ER protein expression was visually scored using total percentages of stained tumor cells and histoscores. Subsequently, mRNA was extracted, and RT-qPCR analysis was performed. Functional ER pathway activity was assessed by a computational Bayesian model inferring ER signaling pathway activity from mRNA levels of ER-specific target genes.

resultsOur analysis of 29 HGSCs shows that neither total percentage of ER protein expression, nor ER histoscores are significantly correlated to ER signaling pathway activity (respectively, p = 0.473 and p = 0.606). Classification of HGSC into three groups based on ER histoscores 0-100 (n = 6), 101-200 (n = 15) and 201-300 (n = 8) resulted in comparable mean ER signaling pathway activity among the groups (p = 0.356). Several samples in the higher ER histoscore groups had low ER signaling pathway activity, indicating that nuclear ER protein expression is not sufficient to describe transcriptional ER activation.

conclusionPositive immunohistochemical ER staining is not always indicative of an active ER signaling pathway and is, therefore, a poor predictor of anti-estrogen response. Further research is needed to prove the predictive value of ER signaling pathway activity regarding anti-estrogen sensitivity in HGSC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEstrogen Receptor alphaFemaleHumansImmunohistochemistryMiddle AgedNeoplasm GradingOvarian NeoplasmsRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSignal TransductionBiomarkers, TumorEstrogen Receptor alphaRNA, MessengerEstrogen receptorHigh-grade serous ovarian carcinomaImmunohistochemistrySignaling pathway activity

Identifiers

PMID33723801
PMCPMC8338831
OpenAlexW3137005975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.